• Publications
  • Influence
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Neuroblastoma is a solid tumour that arises from the developing sympathetic nervous system. Over the past decade, our understanding of this disease has advanced tremendously. The future challenge isExpand
  • 509
  • 28
Association of age at diagnosis and genetic mutations in patients with neuroblastoma.
CONTEXT Neuroblastoma is diagnosed over a wide age range from birth through young adulthood, and older age at diagnosis is associated with a decline in survivability. OBJECTIVE To identify geneticExpand
  • 289
  • 23
Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
Cellular heterogeneity is a hallmark of human neuroblastoma tumors and cell lines. Within a single neuroblastoma are cells from distinct neural crest lineages whose relative abundance is significantExpand
  • 202
  • 17
Association of CYP3A4 genotype with treatment-related leukemia.
Epipodophyllotoxins are associated with leukemias characterized by translocations of the MLL gene at chromosome band 11q23 and other translocations. Cytochrome P450 (CYP) 3A metabolizesExpand
  • 331
  • 13
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
The ALK(F1174L) mutation is associated with intrinsic and acquired resistance to crizotinib and cosegregates with MYCN in neuroblastoma. In this study, we generated a mouse model overexpressingExpand
  • 222
  • 12
Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.
Using a somatic cell hybridization technique, four murine monoclonal antibodies (three immunoglobulin M and one immunoglobulin G3) were produced against a human neuroblastoma cell surface glycolipidExpand
  • 295
  • 11
  • PDF
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
Childhood osteogenic sarcoma (OS) is a rare bone cancer occurring primarily in adolescents. The North American pediatric cooperative groups have performed a series of clinical treatment trials inExpand
  • 167
  • 11
  • PDF
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma
Purpose: Most neuroblastomas initially respond to therapy but many relapse with chemoresistant disease. p53 mutations are rare in diagnostic neuroblastomas, but we have previously reportedExpand
  • 129
  • 10
  • PDF
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.
Neuroblastoma is remarkable for its clinical heterogeneity and is characterized by genomic alterations that are strongly correlated with tumor behavior. The specific genes that influenceExpand
  • 173
  • 9
  • PDF
EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma.
The presence of common genomic deletions in the 19q13 chromosomal region in neuroblastomas and gliomas strongly suggests the presence of a putative tumor suppressor gene for these neoplasms in thisExpand
  • 141
  • 9
  • PDF